Key facts
- ICaPath’s last known valuation is $13.5M (Dec 2025).
- It has raised $5.7M; the latest was Later Stage VC ($4.5M) in Dec 2025.
- Notable investors include TEDCO, Johns Hopkins Technology Ventures, MintPharma Capital, Tedc.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for ICaPath
- ·The full record, as it builds
Funding rounds
No funding rounds for ICaPath are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ICaPath
Developer of a nanoparticle platform intended to precisely specify and quantify the immune response during treatment and subsequent immunosurveillance. The company is developing a broad portfolio of products designed to cure serious diseases in new ways, enabling patients with a new diagnostic test with safe delivery, precise and adaptable dosing, and assuring efficacy.
- Sector
- Healthcare
- HQ
- Baltimore, MD, United States
- Founded
- 2020
- Employees
- 4
- Website
- icapath.com/
- Ownership
- Privately Held (backing)
ICaPath doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ICaPath shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ICaPath in its N-PORT filings yet. We sweep new filings monthly.